Xuexia Liang Qiaodan Liu Wei Yao Shuqin Zhu
10.3389/fonc.2022.941454
Front Oncol
2022 Nov 23;12:941454.
pd-1 inhibitor bevacizumab chemoradiotherapy hepatocellular carcinoma maxillary metastasis
CC BY
https://pubmed.ncbi.nlm.nih.gov/36505782/
Case Reports
PMC9727184
36505782
Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review
2022